Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer

(2010) Yoshito Komatsu et al.   ADVANCES IN THERAPY

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

(2010) Manabu Shiozawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer

(2010) Satoshi Yuuki et al.   CLINICAL DRUG INVESTIGATION

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

(2009) T Yoshioka et al.   BRITISH JOURNAL OF CANCER

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

(2009) A. Tsunoda et al.   ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015

(2007) C.-H. Kohne et al.   ANNALS OF ONCOLOGY